OpenAI acquires Orchestra Bio to build AI tools for drug development
OpenAI announced it acquired biopharma platform Orchestra Bio and will build on its Rosalind life sciences models to streamline drug development. Andrew Curran argued biomedicine is OpenAI's way to turn public sentiment around, starting in 2027, and separately reiterated his claim that Anthropic will announce a bigger biology breakthrough within two weeks. No safety implications were raised in the posts.
All posts · 6, most important first
- We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! openai.com/index/openai-t…1,004 likes · 139 reposts
- Drug discovery, new disease cures, advancements in pharma and biomedicine. Along with direct dividends or shares - as is currently being discussed - these are the only viable ways to turn public sentiment around. The big push will start to happen in 2027.
@openai: We’ve acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Together, we’ll build on Rosalind, our AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner. Welcome @ashokaraj_ and team! openai.com/index/openai-t… open on X17 likes · 3 reposts - I've said a few times Anthropic has a bio breakthrough they will announce before the IPO. The next two weeks sounds right to me.SCOOP: Anthropic will be announcing another biology/process breakthrough in the next two weeks, and it will be even bigger than this one. This was not mentioned in the report, but it was specifically analyst number 3 on this project who found the discovery for the anti-venom. I know it’s not Fable 5.5, and sorry to disappoint some people, but this is an important breakthrough in biology. A group of non-experts from a financial investment research firm worked with Anthropic to direct Claude through a protein discovery campaign, that produced 17 experimentally validated protein binders targeting scorpion neurotoxins. Scorpion stings affect roughly 1.2 million people annually, and these proteins could eventually help develop new antivenoms. This is just the beginning for the discovery process, and us being able to synthesize actual medical products that can help people all around the world! open on X8 likes · 0 reposts
- Right here:SCOOP: Anthropic will be announcing another biology/process breakthrough in the next two weeks, and it will be even bigger than this one. This was not mentioned in the report, but it was specifically analyst number 3 on this project who found the discovery for the anti-venom. I know it’s not Fable 5.5, and sorry to disappoint some people, but this is an important breakthrough in biology. A group of non-experts from a financial investment research firm worked with Anthropic to direct Claude through a protein discovery campaign, that produced 17 experimentally validated protein binders targeting scorpion neurotoxins. Scorpion stings affect roughly 1.2 million people annually, and these proteins could eventually help develop new antivenoms. This is just the beginning for the discovery process, and us being able to synthesize actual medical products that can help people all around the world! open on X1 likes · 0 reposts
- GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration? DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it. That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders. With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets. openai.com/index/scaling-…1,080 likes · 144 reposts
- In the same mouse-brain dataset, GPT-Rosalind found a possible clue to why TSC2 mutations tend to cause more severe tuberous sclerosis than TSC1 mutations. The two genes work together to regulate mTOR. Yet in one group of cerebellar neurons, disrupting TSC2 changed the expression of dozens of genes, including genes involved in neuronal communication. Disrupting TSC1 had little effect on gene expression in the same cell type. Existing treatments already target mTOR. Do they reverse these changes, or is there more to TSC2’s role in these neurons?100 likes · 8 reposts
@openai org · 
@andrewcurran_ commentary ·